Barclays’s Augmedix, Inc. Common Stock AUGX Stock Holding History

Barclays’s Portfolio AUGX Stock Details AUGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-18,372	Closed	-$43.2K	–	5577
2024 Q3	$43.2K	Buy	18,372 +14,941	+435%	+$30.2K	﹤0.01%	4785
2024 Q2	$3.02K	Buy	3,431 +3,231	+1,616%	+$6.66K	﹤0.01%	4614
2024 Q1	$818	Sell	200 -18,655	-99%	-$83.5K	﹤0.01%	4955
2023 Q4	$110K	Sell	18,855 -3,461	-16%	-$18.2K	﹤0.01%	4617
2023 Q3	$115K	Buy	+22,316	New	+$105K	﹤0.01%	3545

Barclays's AUGX Position: Q4 2024 in Review

Barclays sold out of Augmedix, Inc. Common Stock (AUGX) in Q4 2024, closing a stake of 18,372 shares — an estimated $43.2K sold.

Barclays first reported a position in AUGX in Q3 2023 and held it in 5 quarters. The position peaked at $115K in Q3 2023. 0 funds tracked by Wall St. Rank hold AUGX as of Q4 2024.

Barclays reported no remaining Augmedix, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
Barclays sold 18,372 Augmedix, Inc. Common Stock shares in Q4 2024, an estimated $43.2K.
Barclays first reported a position in Augmedix, Inc. Common Stock in Q3 2023 and held it in 5 quarters.
Barclays's Augmedix, Inc. Common Stock position peaked at $115K in Q3 2023.
0 funds tracked by Wall St. Rank held Augmedix, Inc. Common Stock as of Q4 2024.

Based on Barclays's 13F filing for Q4 2024, filed 13 Feb 2025.